Femoral head necrosis occurs mainly in young and middle-aged people between the ages of 30 and 50. Once the femoral head collapses, arthroplasty will be inevitable for most patients. Since artificial joints have a certain lifespan, for young patients, they may have to undergo two or even more joint revision surgeries during their lifetime. Therefore, for these young and middle-aged patients, a less invasive treatment approach should be used to stop the progression of the femoral head lesion and prevent the femoral head from collapsing. Preserving the patient’s own joints and delaying or avoiding arthroplasty is a realistic goal in the treatment of femoral head necrosis. Multi-needle medullary decompression The technique of multiple medullary decompression with a small aperture of a 3 mm drill bit, first reported in 2004, has reduced the collapse rate by 14.3% compared to traditional medullary decompression techniques without the series of complications associated with traditional medullary decompression techniques. Several studies have shown that the success rate achieved in the Ficat I and II stages of medullary decompression group was 71-79%, compared to 35% in the non-surgical treatment group. The success rate was 100% in cases where the extent of femoral head necrosis was < 25% and 84% in cases where the extent of necrosis was between 25% and 50%. Non-vascularized bone grafting The principle of non-vascularized bone grafting in the treatment of femoral head necrosis is to reduce intraosseous pressure in the area of femoral head necrosis, remove the necrotic bone, provide structural support to the subchondral bone, and promote subchondral bone repair and reconstruction. In 1994, Rosenwasser (1994) first used a transcephalic junction window to fully excavate the necrotic bone in the femoral head and then implanted autologous cancellous bone. 2008 results of a study showed that 81.8% of Ficat stage II and 47% of Ficat stage III hips did not require further surgery, with an overall The head preservation rate was 68%. With the use of various growth and differentiation factors such as bone mo rphogenetic protein (BMP) and fibroblast growth factor (FGF), the efficacy of non-vascularized bone grafts will be effectively improved.